Nitasha Gupta, MD
Ophthalmology · New York, NYNPI 1972941748
Payments from drug & device makers
Across 319 payments — averaging $135.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$31K
- AbbVie$2K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Sight Sciences, Inc.$1K
- Alcon$1K
- Carl Zeiss Meditec, Inc.$1K
- plus $5K from 22 others
What the payments were for
- Consulting fees$28,83867%
- Speaking & faculty fees$4291%
- Travel & lodging$1,1933%
- Food & beverage$12,74329%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 46 | $30,937 |
| AbbVie(2 entities) | 86 | $2,202 |
| Johnson & Johnson Surgical Vision, Inc. | 14 | $1,609 |
| Sight Sciences, Inc. | 12 | $1,073 |
| Alcon | 33 | $1,055 |
| Carl Zeiss Meditec, Inc. | 1 | $1,050 |
| Bausch & Lomb Americas Inc. | 20 | $957 |
| Aerie Pharmaceuticals, Inc. | 13 | $748 |
| Novartis | 24 | $490 |
| Amgen(2 entities) | 6 | $411 |
| Astellas Pharma US Inc | 8 | $362 |
| Nova Eye, Inc. | 3 | $356 |
| Heidelberg Engineering, Inc. | 1 | $307 |
| Dompe US, Inc. | 4 | $239 |
| Rxsight Inc | 4 | $218 |
| Sun Pharmaceutical Industries Inc. | 10 | $202 |
| NEW World Medical,inc. | 2 | $198 |
| Tarsus Pharmaceuticals, Inc. | 5 | $140 |
| Biotissue Holdings Inc. | 4 | $127 |
| Oyster Point Pharma, Inc. | 5 | $111 |
| Harrow Eye, LLC | 5 | $96 |
| Mallinckrodt Hospital Products Inc. | 2 | $72 |
| Kala Pharmaceuticals, Inc. | 3 | $70 |
| Oculus Surgical Inc. | 2 | $60 |
| Ocular Therapeutix, Inc. | 2 | $38 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $36 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
| Omeros Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Travoprost Intraocular Implant - iDose$6,770
- VisuMax$1,050
- QUATERA 700$1,050
- CALLISTO eye$1,050
- CIRRUS HD-OCT$1,050
- Tecnis 1-piece IOL$933
- Tecnis 3-piece IOL$933
- Tecnis Symphony IOL$933
- Tecnis Symphony Toric IOL$933
- OMNI(R) SURGICAL SYSTEM (US)$821
- Rhopressa$586
- Rocklatan$586
- XEN GLAUCOMA TREATMENT SYSTEM$492
- iDoseTR$388
- Tecnis IOL$376
- TEPEZZA$361
- Spectralis$307
- iStent Trabecular Micro-Bypass System Model iS3$262
- TORIC$256
- enVista MX60 IOL$248
How this compares
$43,204 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 57 | $36,699 |
| LumiganBimatoprost | 67 | $34,308 |
| RestasisCyclosporine | 16 | $23,823 |
| RhopressaNetarsudil Mesylate | 21 | $12,645 |
| VyzultaLatanoprostene Bunod | 22 | $12,256 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 53 | $11,228 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $10,182 |
| MieboPerfluorohexyloctane/Pf | 13 | $9,630 |
| Prednisolone Acetate | 163 | $9,153 |
| TafluprostTafluprost/Pf | 16 | $5,293 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $5,128 |
| Ketorolac Tromethamine | 162 | $4,989 |
| Alphagan PBrimonidine Tartrate | 18 | $3,707 |
| Pilocarpine Hcl | 54 | $3,088 |
| ZioptanTafluprost/Pf | 12 | $3,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,202 | $72,021119 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $748 | $49,34478 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo | $957 | $21,88635 claims |
| AlconSimbrinza | $1,055 | $5,12822 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $36 | $3,03721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.